Maarten van der Doelen

Chapter 6

3.32, P = 0.003, Figure 2D). In patients with an elevated baseline ALP, the median time to SRE was significantly longer when patients experienced ≥10% ALP decline after the first injection (subgroup 3) when compared to the patients without such ALP reduction (subgroup 4) (14.4 months versus 5.6 months, HR 1.82, 95% CI 1.07-3.09, P = 0.027). 0 100 200 300 400 ALP (U/L) -12 -9 -6 6 9 12 -3 R1 R6 3 Months since start of radium-223 ALP lb/ub 0 500 1000 1500 250 750 1250 PSA (ng/mL) 6 9 12 -3 R1 R6 3 -6 -9 -12 Months since start of radium-223 Figure 3. Biomarker dynamics. A. ALP dynamics before, during and after treatment with radium-223 (median, interquartile range). B. PSA dynamics during and after treatment with radium-223 (median, interquartile range). R1; radium-223 injection 1; R6 radium-223 injection 6. A B PSA lb/ub

164